Anxiety and depression status in patients with idiopathic pulmonary fibrosis and outcomes of nintedanib treatment: an observational study

References

• Lee JH, Park HJ, Kim S, et al. Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study. BMC Pulm Med. 2023;23(1):1. doi: 10.1186/s12890-023-02340-8.[PMC] [
   PubMed Web of Science ®Google Scholar
• Zheng Q, Cox IA, Campbell JA, et al. Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open Res. 2022;8(1):00591–11. doi: 10.1183/23120541.00591-2021.
   PubMedGoogle Scholar
• Holland AE, Fiore JF, Jr., Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014;19(8):1215–11. doi: 10.1111/resp.12360.
   PubMed Web of Science ®Google Scholar
• Coelho AC, Knorst MM, Gazzana MB, et al. Predictors of physical and mental health-related quality of life in patients with interstitial lung disease: a multifactorial analysis. J Bras Pneumol. 2010;36(5):562–570. doi: 10.1590/S1806-37132010000500007.
   PubMed Web of Science ®Google Scholar
• Glaspole IN, Chapman SA, Cooper WA, et al. Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF registry. Respirology. 2017;22(5):950–956. doi: 10.1111/resp.12989.
   PubMed Web of Science ®Google Scholar
• Antoniou K, Kamekis A, Symvoulakis EK, et al. Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review. Curr Opin Pulm Med. 2020;26(5):457–463. doi: 10.1097/MCP.0000000000000703.
   PubMed Web of Science ®Google Scholar
• Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434–1445. doi: 10.1183/09031936.00174914.
   PubMed Web of Science ®Google Scholar
• Takeda T, Takeuchi M, Saitoh M, et al. Improvement in patient-reported outcomes and forced vital capacity during nintedanib treatment of idiopathic pulmonary fibrosis. Tohoku J Exp Med. 2018;245(2):107–114. doi: 10.1620/tjem.245.107.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med. 2016;113:74–79. doi: 10.1016/j.rmed.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. doi: 10.1164/rccm.201807-1255ST.
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med. 1991;85(Suppl B):25–31. discussion 33-27. doi: 10.1016/S0954-6111(06)80166-6.
   PubMed Web of Science ®Google Scholar
• ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–1097. doi: 10.1001/archinte.166.10.1092.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
   PubMed Web of Science ®Google Scholar
• Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64(2):258–266. doi: 10.1097/00006842-200203000-00008.
   PubMed Web of Science ®Google Scholar
• Glaspole IN, Watson AL, Allan H, et al. Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(2):1700168. doi: 10.1183/13993003.00168-2017.
   PubMed Web of Science ®Google Scholar
• Maqhuzu PN, Kreuter M, Bahmer T, et al. Cost drivers in the pharmacological treatment of interstitial lung disease. Respir Res. 2021;22(1):218. doi: 10.1186/s12931-021-01807-8.
   PubMed Web of Science ®Google Scholar
• Liu QW, Qin T, Hu B, et al. Relationship between illness perception, fear of progression and quality of life in interstitial lung disease patients: a cross-sectional study. J Clin Nurs. 2021;30(23–24):3493–3505. doi: 10.1111/jocn.15852.
   PubMed Web of Science ®Google Scholar
• Evatt DP, Kassel JD. Smoking, arousal, and affect: the role of anxiety sensitivity. J Anxiety Disord. 2010;24(1):114–123. doi: 10.1016/j.janxdis.2009.09.006.
   PubMed Web of Science ®Google Scholar
• Wu Z, Yue Q, Zhao Z, et al. A cross-sectional study of smoking and depression among US adults: NHANES (2005-2018). Front Public Health. 2023;11:1081706. doi: 10.3389/fpubh.2023.1081706.
   PubMed Web of Science ®Google Scholar
• Bjelland I, Krokstad S, Mykletun A, et al. Does a higher educational level protect against anxiety and depression? The HUNT study. Soc Sci Med. 2008;66(6):1334–1345. doi: 10.1016/j.socscimed.2007.12.019.
   PubMed Web of Science ®Google Scholar
• Barrenetxea J, Pan A, Feng Q, et al. Factors associated with depression across age groups of older adults: the Singapore Chinese health study. Int J Geriatr Psychiatry. 2022;37(2):1–12.
   Web of Science ®Google Scholar
• Ma M, Shi Z, Wu H, et al. Clinical implications of panic attack in Chinese patients with somatoform disorders. J Psychosom Res. 2021;146:110509. doi: 10.1016/j.jpsychores.2021.110509.
   PubMed Web of Science ®Google Scholar
• Uhlenbusch N, Löwe B, Härter M, et al. Depression and anxiety in patients with different rare chronic diseases: a cross-sectional study. PLOS One. 2019;14(2):e0211343. doi: 10.1371/journal.pone.0211343.
   PubMed Web of Science ®Google Scholar
• Seppälä S, Rajala K, Lehto JT, et al. Factor analysis identifies three separate symptom clusters in idiopathic pulmonary fibrosis. ERJ Open Res. 2020;6(4):00347–2020. doi: 10.1183/23120541.00347-2020.
   PubMedGoogle Scholar
• Zhang H, Wang Y, Lou H, et al. Prevalence of and factors associated with alexithymia among patients with chronic obstructive pulmonary disease in China: a cross-sectional study. BMC Pulm Med. 2023;23(1):40. doi: 10.1186/s12890-023-02335-5.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Molyneaux PL, Bernardinello N, et al. The role of the lung's microbiome in the pathogenesis and progression of idiopathic pulmonary fibrosis. Int J Mol Sci. 2019;20(22):5618. doi: 10.3390/ijms20225618.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Sekine A, Baba T, et al. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2019;19(1):78. doi: 10.1186/s12890-019-0841-7.
   PubMedGoogle Scholar
• Ikeda S, Sekine A, Baba T, et al. Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: a single-center experience. Respir Investig. 2017;55(1):51–54. doi: 10.1016/j.resinv.2016.08.003.
   PubMed Web of Science ®Google Scholar
• Hirasawa Y, Abe M, Terada J, et al. Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther. 2020;62:101917. doi: 10.1016/j.pupt.2020.101917.
   PubMed Web of Science ®Google Scholar
• Xu Z, Li H, Wen F, et al. Subgroup analysis for Chinese patients included in the INPULSIS((R)) trials on nintedanib in idiopathic pulmonary fibrosis. Adv Ther. 2019;36(3):621–631. doi: 10.1007/s12325-019-0887-1.
   PubMed Web of Science ®Google Scholar
• Stoop CH, Nefs G, Pommer AM, et al. Effectiveness of a stepped care intervention for anxiety and depression in people with diabetes, asthma or COPD in primary care: a randomized controlled trial. J Affect Disord. 2015;184:269–276. doi: 10.1016/j.jad.2015.05.063.
   PubMed Web of Science ®Google Scholar
• Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands study of depression and anxiety (NESDA.)[J Clin Psychiatry. 2011;72(3):341–348. doi: 10.4088/JCP.10m06176blu.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang X. [Somatization symptoms in lung cancer patients and correlative analysis between anxiety, depression and somatization symptoms]. Zhongguo Fei Ai Za Zhi. 2017;20(7):473–478.
   PubMedGoogle Scholar
• Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev. 2014;23(133):345–349. doi: 10.1183/09059180.00007813.
   PubMedGoogle Scholar